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Clinimetrics: Grading of Recommendations, Assessment, Development and
Evaluation (GRADE)
SummaryDescription: The Grading of Recommendations, Assessment,
Development and Evaluation (GRADE) is a framework for assessing the
quality (or certainty) of evidence and grading the strength of
recommendations in healthcare.1 The GRADE system has been
endorsed by many organisations and it is becoming an international
standard for use in judging the evidence in systematic reviews and
clinical guidelines. This Clinimetrics paper only considers GRADE when
used to judge evidence on treatment effects,2 although the GRADE
system can also rate the quality of evidence from diagnostic,3
prognostic4 and qualitative research.5
The quality of evidence is applied to each outcome and is rated at one
of four levels: high, moderate, low and very low.1 These levels imply a
gradient of confidence in estimates of summary measures of treatment
effect. Randomised controlled trials begin as high quality and observa-
tional studies begin as low quality. The confidence in the evidence can be
decreased for five reasons: study limitations (risk of bias, such as lack of
allocation concealment or blinding); inconsistency of results (heteroge-
neity or variability of point estimates and overlap of confidence intervals);
indirectness of evidence (differences in populations, interventions,
comparators or outcomes); imprecision of estimates (wide confidence
intervals crossing a decision threshold); and publication bias (missing
evidence, typically from studies that show no effect). Three situations
could upgrade the quality of evidence: when the magnitude of the
treatment effect is very large, if all plausible biases (confounding) would
reduce a demonstrated effect and if there is evidence of a dose-response
relationship.
GRADE provides two levels of recommendations – strong or weak –
in favour of or against an intervention.6 The strength of recommen-
dation considers three factors: the balance between benefits and
harms, variability in patients’ preferences and values, and whether thehttps://doi.org/10.1016/j.jphys.2020.07.003
1836-9553/© 2020 Australian Physiotherapy Association. Published by Elsevier B.V. This is
licenses/by-nc-nd/4.0/).intervention represents a wise use of resources. Online learning
modules are available for the training of authors of systematic reviews
and guideline developers, with most modules lasting no longer than 20
minutes.7 The GRADE Working Group website also provides a list of
publications and an online handbook for using GRADE and GRADEpro
software.8
Clinimetric properties: In the first iteration of GRADE there was
‘fair’ inter-rater reliability for rating quality of evidence (kappa = 0.40).2
After more guidance on how to use GRADE there was ‘good’ inter-rater
reliability among inexperienced raters who received training on the
GRADE methodology (intraclass correlation coefficient [ICC] = 0.66) and
among members of the GRADE Working Group (ICC = 0.72).9 The
inter-rater reliability for quality of evidence has been shown to increase
with training and with ratings by groups of three or four raters, but not
when GRADE was assessed through a consensus rating.9
The inter-rater reliability for the individual GRADE domains was
‘poor’ to ‘moderate’ for risk of bias (kappa = 0.06 to 0.41), ‘fair’ to
‘excellent’ for inconsistency (kappa = 0.37 to 0.84), and ‘poor’ to
‘moderate’ for imprecision (kappa = 0.18 to 0.21), while for
indirectness agreement varied between 41% and 100% of cases.10 Among
guideline panel members, there was ‘fair’ inter-rater reliability for bal-
ance of benefit and harms (kappa = 0.4) and use of resources (kappa =
0.28), ‘moderate’ for patients’ preferences and values (kappa = 0.44),
‘fair’ for assessing the strength of recommendations (kappa = 0.39), and
‘good’ for making recommendations (kappa = 0.74).11
The standard GRADE assessment had ‘good’ agreement (kappa =
0.66) with Trial Sequential Analysis for rating imprecision,12 and ‘fair’
agreement (kappa = 0.35) for rating quality of evidence with the Semi-
Automated Quality Assessment Tool, which is a 30-item checklist
covering key determinants of the five GRADE domains.13,14CommentaryGRADE is an essential tool for reviewers and decision-makers as it
provides an indication of the confidence they can place in the results
and a mechanism with which to translate the evidence into clinical
practice guidelines. The initial work on GRADE reliability was con-
ducted when limited guidance was available, resulting in many dis-
agreements, but more detailed guidance seems to have improved inter-
rater reliability. Specific training on GRADE methodology is recom-
mended for inexperienced raters, and two independent raters are
sufficient to reliably assess the quality of evidence. The basis for
judgements should be made transparent and reported. Application of
GRADE can be complex, as evidenced by a series of publications15 and a
lengthy handbook with over 10 chapters.8 Different applications of
GRADE and adaptations are likely to yield inconsistencies in ratings,
which could influence decision-making. To maximise agreement,
further research on assistive tools for GRADE assessment13,14 is war-
ranted.
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